A trial of Proxyphylline in the Treatment of Chronic Obstructive Airways Disease

Dinda, P. K.; Chatterjee, Sharmistha; Wd, Riding; Singh, Thounaojam Amusana

doi:10.1111/j.1742-1241.1969.tb04341.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1972

1975

Publication Types

Select...

Book1

Article1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 7 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Chapter 9. Pulmonary and Antiallergy Agents

Tozzi¹

1972

Annual Reports in Medicinal Chemistry

View full text Add to dashboard Cite

Chapter 9. Pulmonary and Antiallergy Agents

Tozzi¹

1972

Annual Reports in Medicinal Chemistry

View full text Add to dashboard Cite

The Bioavailability of a New Sustained‐Release Preparation of Proxiphylline (Neofyllin Retard®) in the Guinea Pig

Larsen¹

1975

Acta Pharmacologica et Toxicologica

View full text Add to dashboard Cite

The bioavailability of a new sustained-release preparation of proxiphylline (neofyllin retard@) has been compared with that of the conventional tablet. The antagonistic action on histamine induced bronchoconstriction in the guinea pig has been used as effect parameter. The results indicate that the release of proxiphylline from the conventional tablet occurred within 85 min. with a maximum antagonistic action of 95 % reached after 70 min., whereas that of the sustained-release preparation was effected more slowly over a period of at least 190 min., resulting in a stable antagonistic action of about 40 % during most of the experimental period. A quantitative analysis of tablets placed in the duodenum for different lengths of time and of the residual amount of proxiphylline in the intestinal content has confirmed that the different shape of the time effect curves obtained with the two tablet formulations is due to a slower release of proxiphylline from the sustained-release tablet than from the conventional tablet. The described in vivo model in the guinea pig has proved useful for the evaluation of the release-and absorption pattern of new sustained-release formulations of anti-asthmatic drugs.

show abstract

A trial of Proxyphylline in the Treatment of Chronic Obstructive Airways Disease

Cited by 2 publications

References 7 publications

Chapter 9. Pulmonary and Antiallergy Agents

Chapter 9. Pulmonary and Antiallergy Agents

The Bioavailability of a New Sustained‐Release Preparation of Proxiphylline (Neofyllin Retard®) in the Guinea Pig

Contact Info

Product

Resources

About